Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Drug maker AbbVie named current President and Chief Operating Officer Robert Michael to succeed Richard Gonzalez as CEO, effective July 1.

AbbVie Names New CEO. The Stock's Not Moving.

Michael, who is AbbVie's chief operating officer, will become the company's second-ever CEO since the company spun out from Abbott Laboratories in 2013.

AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez

AbbVie said on Tuesday that Richard Gonzalez will step down from his role as chief executive officer of the drugmaker on July 1.

AbbVie says Richard Gonzalez to step down as CEO

Richard A. Gonzalez to retire as AbbVie CEO to become Executive Chairman Transition will occur on July 1, 2024 NORTH CHICAGO, Ill. , Feb. 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A.

AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer

Eli Lilly

Vertex Pharmaceuticals

AbbVie is finding ways to grow despite losing patent exclusivity for its blockbuster, Humira. Eli Lilly has delivered impressive growth over the last 12 months, and more could be on the way.

3 Magnificent Growth Stocks to Buy Right Now

– A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVie's commitment to produce a portfolio of products that aim to improve the lives of patients living with inflammatory bowel diseases (IBD) – Oral data presentations include a new post-hoc analysis of clinical and endoscopic outcomes from the SEQUENCE trial comparing risankizumab (SKYRIZI®) versus ustekinumab, results from the COMMAND Phase 3 study of risankizumab as a maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC), and long-term safety results from the U-ENDURE trial of upadacitinib (RINVOQ®) in adult patients with moderately to severely active Crohn's disease (CD) – Research accepted for presentation reiterates AbbVie's commitment to understanding the needs of the gastroenterology community and advance standards of care in IBD NORTH CHICAGO, Ill. , Feb. 19, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that 17 AbbVie-sponsored abstracts, including new data from its inflammatory bowel disease (IBD) portfolio, have been accepted for presentation at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.

AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)

CVS Health

QUALCOMM

What are cash cow stocks? If “Jeopardy!

3 Cash Cows to Boost Your Confidence During the February Chill

Apple

Automatic Data Processing

American Tower

Air Products and Chemicals

Alexandria Real Estate Equities

Brookfield Renewable Partners

Brookfield Infrastructure

Blackrock Inc

Brookfield Corp

Colgate-Palmolive

CME Group

Cummins

Canadian Natural Resources

Equinix

Fortis

Genuine Parts

Home Depot

Honeywell

Hershey

The mid-yielders must offer a decent dividend, but also a decent dividend triangle.

Favorite Mid-Yielders - January Dividend Income Report

ImmunoGen

Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.

AbbVie Cuts Its Guidance on ImmunoGen Deal

AbbVie Inc.'s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The company said it now expects first-quarter per-share earnings to range from $2.26 to $2.30, down from prior guidance of $2.30 to $2.34, including a 4 cent per share dilutive impact from the Immunogen deal.

AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close

Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $11.05-$11.25 which now includes a $0.42 per share dilutive impact related to the ImmunoGen acquisition and the pending Cerevel Therapeutics acquisition AbbVie updates previously issued 2024 first-quarter adjusted diluted EPS guidance range from $2.30-$2.34 to $2.26-$2.30 which now includes a $0.04 per share dilutive impact related to the ImmunoGen acquisition NORTH CHICAGO, Ill. , Feb. 12, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN).

AbbVie Completes Acquisition of ImmunoGen

AbbVie's next-gen immunology superstars are well on their way to replacing Humira. The company is also an excellent dividend stock.

These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy

Abbott Labs

Allianz SE

Advanced Micro Devices

Ares Capital

Broadcom

British American Tobacco

Chevron

Enterprise Products Partners

FedEx

iShares Core MSCI Europe ETF

McDonald's

Altria

NextEra Energy

NVIDIA

Realty Income Corp

PepsiCo

Schwab US Dividend Equity ETF

SPDR S&P 500 ETF Trust

AT&T

Taiwan Semiconductor Manufacturing

Texas Instruments

Reaching retirement and having enough capital to build a dividend money machine are dreams shared by many. With life expectancy on the rise, high yield alone is no longer sufficient; we need to plan for both capital appreciation and dividend growth.

How I Would Invest $1,000,000 And Live Of Dividends Forever

American Express

Spotify

Investors know the phrase “let your winners run,” but it's easier said than done. The temptation to take profits off the table is often too great to ignore.

3 Stocks Just Hit New 52-Week Highs. Should You Still Be Buying?

Archer-Daniels-Midland Company

Amcor Plc

Franklin Resources

Essex Property Trust

Fastenal

Federal Realty Investment Trust

Hormel Foods

Johnson & Johnson

Kimberly-Clark

Kenvue

T. Rowe Price Group

V.F.

Walgreens

Exxon Mobil

"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com. 67 Aristocrats, screened as of February 5, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 11.95%-40.69% topped-by APD & ADM.

5 Dividend Aristocrats Signal Buy In February And 6 To Watch

News for AbbVie Stock (ABBV)